Fig. 5

SMURF2 was targeted by miR-216a-3p in HASMCs. A The potential binding sites of miR-216a-3p and SMURF2 were predicted by starBase v2.0. B Relative luciferase activity was determined in HASMCs co-introduction with SMURF2 3’UTR-WT/MUT and miR-216a-3p/miRNA-NC (ANOVA). C SMURF2 mRNA expression was determined by qRT-PCR in whole blood samples of childhood asthma patients (t-test). D SMURF2 protein expression was measured using western blot assay in HASMCs exposed to different concentrations of PDGF-BB (ANOVA). The blots have been cropped. E The correlation between SMURF2 level and miR-216a-3p expression was analyzed in whole blood samples of childhood asthma patients. F and G MiR-216a-3p expression and SMURF2 protein expression were examined in HASMCs or HASMCs treated with PDGF-BB, PDGF-BB + miR-NC, PDGF-BB + miR-216a-3p, PDGF-BB + anti-miR-NC, or PDGF-BB + anti-miR-216a-3p (ANOVA). The blots have been cropped. *P < 0.05